You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨CXO板塊集體上升,花旗稱藥明康德和藥明生物股價被低估
港股市場CXO板塊集體上升,其中,藥明生物、藥明康德升超4%,泰格醫藥升3%,凱萊英、康龍化成、金斯瑞升超2%。美國眾議院日前以306票對81票通過《生物安全法》法案,接下來將提交參議院。彭博行業研究認為,該提案最終成為法律的概率高達70%,因為其在參眾兩院都獲得強有力的支持。花旗最新發表報吿指,美眾院通過《生物安全法案》,目前未清楚美參議院會否採用眾議院版本的《生物安全法案》或另一個版本,或對《生物安全法案》附加更大法案(a larger bill)。該行相信藥明康德和藥明生物股價被低估,但不確定性影響投資者對CXO板塊信心。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account